Home / Pharma News

Pharma News

Pfizer antibiotics banned across the EU

An inspection by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has resulted in the ban of several drugs produced by a Pfizer manufacturing site in India. 

EMA reports ‘critical deficiencies’ in Chinese API producer Jinan Jinda

A recent European Medicines Agency’s (EMA) follow up on Jinan Jinda Pharmaceutical Chemi Co Ltd (Jinan Jinda) revealed that the Chinese pharmaceutical company is far off meeting EU standards.

Fosun Pharma to acquire Gland in largest acquisition by a Chinese company in India

Shanghai Fosun Pharmaceutical Group Co Ltd (Fosun Pharma) will acquire an 86% stake in Gland Pharma Ltd for an estimated US$1.2–1.5 billion in China’s largest ever takeover of a company in India.

Mylan receives EU go-ahead to purchase Meda, with conditions

The European Commission (EC) has approved the multi-billion dollar acquisition of Swedish specialty pharmaceutical company Meda by Mylan, one of the world’s largest generics and specialty pharmaceutical companies, subject to certain conditions.

Teva to acquire US-based generics maker Anda

Israeli generics giant Teva Pharmaceutical Industries (Teva) announced on 3 August 2016 that it had entered into a definitive agreement to buy US generics business Anda from Allergan.

Amgen and Daiichi Sankyo make deal for biosimilars in Japan

US-based biologicals specialist Amgen and Japan-based Daiichi Sankyo announced on 13 July 2016 that they had made an exclusive agreement to commercialize nine biosimilars in Japan.

Teva generics being snapped up by rivals

There has been a rush on Teva Pharmaceutical Industries (Teva) generics recently, with another round of companies clambering over the pickings.

UK’s DoH says most medicines do not experience shortages

The UK’s Department of Health (DoH) has said that the ‘vast majority’ of prescriptions in the country are not subject to supply problems.

AMRI acquires API maker Euticals

US-based Albany Molecular Research Inc (AMRI) announced on 5 May 2016 that it had entered into a definitive agreement to buy Prime European Therapeuticals, also known as Euticals.

Lannett to co-develop biosimilar insulin product with Chinese partner

US generics maker Lannett Company (Lannett) announced on 22 April 2016 plans to co-develop a biosimilar insulin product for the US market with its strategic partner in China, Yichang HEC Changjiang Pharmaceutical (Yichang), which is part of the HEC Group.

Generics News Research General

more

Biosimilars News Research General

more